ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2026
Inhibition of the EP300/Notch Signaling Pathway Regulates Proliferation and Apoptosis in Oral Squamous Cell Carcinoma.
Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveOral squamous cell carcinoma (OSCC) is highly recurrent and metastatic; EP300 drives tumorigenesis, but its mechanism is unclear. MATERIALS AND
methodsEP300 expression was profiled in OSCC via databases, RT-PCR, and Western blot. Knockdown effects on proliferation (CCK-8, colony), cell cycle, and apoptosis (flow cytometry) were measured. EP300-Notch interplay was probed with Valproic acid, a Notch signaling activator (VPA) rescue assays.
resultsOur experimental results showed that EP300 was upregulated in OSCC Cell Lines. In addition, bioinformatics analysis showed that EP300 upregulation was significantly associated with poor prognosis of OSCC. Prior research and bioinformatics analyses have demonstrated a close relationship between EP300 and the activation of the notch signaling pathway in OSCC. After EP300 knockdown in OSCC cells treated with VPA, our results indicated that VPA could partially reverse the effects of EP300 knockdown on cell proliferation, cell cycle, apoptosis, and EMT processes in OSCC Cells.
conclusionIn this study, we observed that EP300 knockdown suppressed the Notch signaling pathway, consequently inhibiting OSCC cell proliferation, the cell cycle, and EMT while also promoting apoptosis. These findings suggest that EP300 is crucial for OSCC cell growth and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.